Novocure: +17% Since Our Initial Recommendation in the MAGAZINE Three Weeks Ago
Three weeks ago, we have presented the Amercian oncology company Novocure as a HOT STOCK in our monthly Biotech Investments MAGAZINE. Since then, the share has gained more than 17%.
BioNovocure is working on a ground-breaking new technology to treat some of the most aggressive forms of cancer. The company is headquartered in Jersey and has offices in the US, Japan, Germany, Switzerland and Israel. Novocure is growing rapidly and was able to increase its net income at an average rate of 28% in the last 5 years.
By using physics to treat cancer, Novocure is following a revolutionary new approach to tackle this devastating disease. The technology of so-called Tumor Treating Fields utilizes the natural electrical properties of dividing cancer cells by applying specific frequencies to tumor cells, thereby interfering with cell division and tumor growth.
Novocure’s products are approved in the US, Israel and several European countries for the treatment of adult patients with glioblastoma, the most common and aggressive type of brain tumor with a very poor prognosis. In addition, the company holds a marketing authorization in the US for the treatment of patients with malignant pleural mesothelioma, a relatively rare but highly aggressive form of cancer affecting the membrane covering the lungs and ribs.
Moreover, Novocure has ongoing or completed phase 3 clinical trials investigating the therapeutic potential of Tumor Treating Fields in pancreatic cancer, ovarian cancer, non-small cell lung cancer and brain metastases.
Biotech Investments sees great value in Novocure’s approach and is highly confident for the prospects of this company. HOT STOCK!
Would you like to know more about other biotech hot stocks? You can find lots of great articles in our free monthly Biotech Investments MAGAZINE.
- Just send an email with “MAGAZINE” to firstname.lastname@example.org
- You will receive it immediately by email
- Enjoy reading, it’s entirely free